The DOI matches its Crossref record.
Precision Medicine—Personalized, Problematic, and Promising
Abstract
Precision medicine is a term used to describe individualized treatment that encompasses the use of new diagnostics and therapeutics, targeted to the needs of a patient based on his/her own genetic, biomarker, phenotypic, or psychosocial characteristics. In particular, advances such as cell sorting, epigenetics, proteomics, metabolomics, and more are converging with informatics and other technologies in a manner that is rapidly expanding the scope of this field. This article highlights the variety of breakthroughs in the field and addresses challenges that precision medicine may face. Many current technologies are rapidly enhancing the field of precision medicine. Recombinant biologic agents can now be used as replacement therapies, such as in the treatment of hemophilia, and electronic health records have created a rich and accessible database of clinical information that can be used for research and for clinical care guideline creation. Gene therapy, genetics, and next-generation DNA sequencing methods are perhaps having the greatest effect; this will continue to advance with decreases in costs. Testing for specific abnormalities has aided in the treatment of certain types of cancers. In lung cancer, molecular testing of EGFR, MET, RAS, ALK, and other genetic markers can help identify patients who need treatment and protect patients who do not from costly and toxic therapies. Molecular testing can also screen patients for multiple endocrine neoplasia type 2, which allows for early prophylactic treatment and attention, sparing unaffected family members from unnecessary screening. Such advances decrease harm and create care specific to the individual. However, there are also challenges. One challenge is the misalignment of patient, physician, health system, payer, and industry interests. In greater detail, patients and physicians are primarily concerned with understanding and treating disease, but physicians must also consider utilization of heath care, which affects the health care system, payer, and industry interests and in turn also relates to costs of new diagnostics or finding more profitable therapies. Managing these interests in an efficacious and cost-effective manner may prove difficult. A second challenge is organizing the wealth of growing information. As disease classification trends toward more precise definitions and discrete disease entities, expanded decision algorithms and treatment options will be needed to properly address each type of treatment. Some conditions are caused by multiple different mutations in different genes, whereas in other cases different mutations in a single gene may lead to a range of diseases. As the complexity of disease becomes more apparent to us, physicians, especially primary care providers, will need to utilize informatics all within clinical guidelines in order to navigate these complex and specialized referral pathways. Future trends in precision medicine are most likely in targeting genetic pathways in cancer with medications, cancer immunotherapies, DNA sequencing, and use of technology in acute interventions (eg, automated defibrillator). Should stakeholders adapt to these changes, health providers streamline pathways that facilitate specialist access and proper care, and agencies and payers support a cost-effective field, then the advances in precision medicine may be limitless.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
A survey on digital twin: definitions, characteristics, applications, and design implications
Barricelli, B. R., Casiraghi, E., & Fogli, D. (2019) · IEEE Access · doi:10.1109/access.2019.2953499 · Cited by 1,480
Wearable and flexible electronics for continuous molecular monitoring
Yang, Y., & Gao, W. (2019) · Chemical Society Reviews · doi:10.1039/c7cs00730b · Cited by 1,315
Electronic Textiles for Wearable Point-of-Care Systems
Chen, G., Xiao, X., Zhao, X., Tat, T., Bick, M., & Chen, J. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00502 · Cited by 688
A review on longitudinal data analysis with random forest
Hu, J., & Szymczak, S. (2023) · Briefings in Bioinformatics · doi:10.1093/bib/bbad002 · Cited by 678
Reinforcement Learning in Healthcare: A Survey
Yu, C., Liu, J., Nemati, S., & Yin, G. (2023) · ACM Computing Surveys · doi:10.1145/3477600 · Cited by 628
Metadata
- Authors
- Larry Jameson, J., & Longo, D. L.
- Venue
- Obstetrical & Gynecological Survey
- Published
- 2015-10
- Volume
- 70
- Issue
- 10
- Pages
- 612-614
- ISSN
- 0029-7828 (ISSN-L)
- OpenAlex
- W2978737563
- Cited by
- 277
- References
- 0
- FWCI
- 21.03
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Precision Medicine—Personalized, Problematic, and Promising. https://app.cochat.ai/papers/10.1097/01.ogx.0000472121.21647.38
- The paper
- Larry Jameson, J., & Longo, D. L. (2015). Precision Medicine—Personalized, Problematic, and Promising. Obstetrical & Gynecological Survey. https://doi.org/10.1097/01.ogx.0000472121.21647.38
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.